Here’s a look at some of the latest news in prostate cancer:
The New York Times published an in-depth article about prostate cancer and theFrom “No Answers For Men With Prostate Cancer,”
Last year, 218,000 men were diagnosed with prostate cancer, but nobody can tell them what type of treatment is most likely to save their life.
Leah is the wife of Ted, who is undergoing prostate cancer treatment. She writes about the Top Ten Reasons To Get Prostate Cancer:
Some months ago I pulled up an article about a doctor who was making a presentation at a conference. But before he reported the results of his PC research, he felt compelled to say, “You know, ”Prostate Cancer is not a trivial disease.”
A new development in the fight against cancer: Recent research at the University of Haifa found that molecules found in common fungus Ganoderma lucidum aid in suppressing some of the mechanisms involved in the progression of prostate cancer. The main action of the fungus: disrupting androgen receptor activity and impeding the proliferation of cancerous cells.
A world-first therapeutic vaccine for prostate cancer could be available in five years’ time, an Australian researcher says.
One in nine Australian men are diagnosed with prostate cancer each year and more than 3,000 die from it.
Brisbane’s Mater Medical Research Institute (MMRI) is conducting phase one clinical trials on the white dendritic cell vaccine which helps “re-educate” a patient’s immune system.
The American College of Preventive Medicine has found there is not enough evidence to recommend for or against routine prostate cancer screening with digital rectal examination (DRE) or the PSA test.
The physicians group issued a position statement earlier today following a review of existing studies of the practice of screening men for prostate cancer. The statement further adds to a long-standing controversy among men’s healthcare professionals. The review appears in the February issue of the American Journal of Preventive Medicine.